Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pasquier

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
European Urology Oncology|February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 StudyDavid Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.
Plos One|March 18, 2016
Harmonization of the Volume of Interest Delineation among All Eleven Radiotherapy Centers in the North of FranceDavid Pasquier, Laurence Boutaud de la Combe-Chossiere, Damien Carlier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 15, 2026
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trialHugo Corda, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
International Journal of Cancer|April 30, 2022
CANTO-RT: Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancerSofiane Allali, Matthieu Carton, Thomas Sarrade, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2025
Clinical characteristics and management of long survivors in extensive stage small cell lung cancerElisa Gobbini, Mamadou Hassimiou Diallo, David Pasquier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2021
Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladderJonathan Khalifa, Stéphane Supiot, Géraldine Pignot, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2020
Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group DatabaseJean-Michel Hannoun-Levi, Jocelyn Gal, Erik Van Limbergen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2022
Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohortYoussef Ghannam, Antonio Di Meglio, Thomas Sarrade, et al.
European Urology Oncology|June 11, 2026
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate CancerQuentin Josset, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
Lancet (London, England)|March 7, 2026
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trialSofia Rivera, Robabeh Ghodssighassemabadi, Guillaume Auzac, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
European Urology Oncology|February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 StudyDavid Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.
Plos One|March 18, 2016
Harmonization of the Volume of Interest Delineation among All Eleven Radiotherapy Centers in the North of FranceDavid Pasquier, Laurence Boutaud de la Combe-Chossiere, Damien Carlier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 15, 2026
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trialHugo Corda, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
International Journal of Cancer|April 30, 2022
CANTO-RT: Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancerSofiane Allali, Matthieu Carton, Thomas Sarrade, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2025
Clinical characteristics and management of long survivors in extensive stage small cell lung cancerElisa Gobbini, Mamadou Hassimiou Diallo, David Pasquier, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2021
Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladderJonathan Khalifa, Stéphane Supiot, Géraldine Pignot, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2020
Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group DatabaseJean-Michel Hannoun-Levi, Jocelyn Gal, Erik Van Limbergen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2022
Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohortYoussef Ghannam, Antonio Di Meglio, Thomas Sarrade, et al.
European Urology Oncology|June 11, 2026
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate CancerQuentin Josset, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
Lancet (London, England)|March 7, 2026
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trialSofia Rivera, Robabeh Ghodssighassemabadi, Guillaume Auzac, et al.
Pageof 16